Literature DB >> 16457947

Neuron-specific enolase and tau protein as neurobiochemical markers of neuronal damage are related to early clinical course and long-term outcome in acute ischemic stroke.

Michael T Wunderlich1, Hartmut Lins, Martin Skalej, Claus-W Wallesch, Michael Goertler.   

Abstract

OBJECTIVES: Analyses of neuron-specific enolase (NSE) and tau protein in patients with hyperacute ischemic stroke, their association with infarct volume, severity of the neurological deficit, the neurovascular status and functional outcome. PATIENTS AND METHODS: In 66 consecutive patients, serial venous blood samples were taken at 3, 6, 12, 18, 24, 48, 72, 96, and 120 h after stroke onset. The neurovascular status was assessed by repetitive extra- and transcranial duplex sonography. Neurological deficits were quantified by the NIH stroke scale, and functional outcome was assessed with the modified Rankin scale (mRS).
RESULTS: After a first rise within 3 h, NSE decreased followed by a secondary increase until Day 5. Tau protein concentrations showed a continuous increase from admission onward. NSE and tau release were highly correlated with severity of neurological deficits and infarct volume (P = 0.001). NSE, but not tau protein, release was associated to the neurovascular status on admission. NSE and tau protein values were significantly correlated with the functional outcome at 3 months (P < 0.001).
CONCLUSION: Release kinetics of NSE and tau protein are associated with patients' clinical deficits and infarct volume, and may be used as an additional predictor of the early course and functional outcome.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16457947     DOI: 10.1016/j.clineuro.2005.12.006

Source DB:  PubMed          Journal:  Clin Neurol Neurosurg        ISSN: 0303-8467            Impact factor:   1.876


  54 in total

Review 1.  Cerebrospinal fluid biomarker candidates of schizophrenia: where do we stand?

Authors:  Nenad Vasic; Bernhard J Connemann; Robert C Wolf; Hayrettin Tumani; Johannes Brettschneider
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2011-12-16       Impact factor: 5.270

2.  Tau as a biomarker of neurodegenerative diseases.

Authors:  Susanna Schraen-Maschke; Nicolas Sergeant; Claire-Marie Dhaenens; Stéphanie Bombois; Vincent Deramecourt; Marie-Laure Caillet-Boudin; Florence Pasquier; Claude-Alain Maurage; Bernard Sablonnière; Eugeen Vanmechelen; Luc Buée
Journal:  Biomark Med       Date:  2008-08       Impact factor: 2.851

Review 3.  Blood biomarkers of ischemic stroke.

Authors:  Glen C Jickling; Frank R Sharp
Journal:  Neurotherapeutics       Date:  2011-07       Impact factor: 7.620

4.  Serum tau protein as a marker for the diagnosis of Creutzfeldt-Jakob disease.

Authors:  Moeko Noguchi-Shinohara; Tsuyoshi Hamaguchi; Ichiro Nozaki; Kenji Sakai; Masahito Yamada
Journal:  J Neurol       Date:  2011-03-01       Impact factor: 4.849

5.  Increased cerebrospinal fluid and serum levels of S100B in first-onset schizophrenia are not related to a degenerative release of glial fibrillar acidic protein, myelin basic protein and neurone-specific enolase from glia or neurones.

Authors:  J Steiner; H Bielau; H-G Bernstein; B Bogerts; M T Wunderlich
Journal:  J Neurol Neurosurg Psychiatry       Date:  2006-11       Impact factor: 10.154

6.  Liquid biopsy markers for stroke diagnosis.

Authors:  Harshani Wijerathne; Malgorzata A Witek; Alison E Baird; Steven A Soper
Journal:  Expert Rev Mol Diagn       Date:  2020-07-05       Impact factor: 5.225

7.  Tau is reduced in AD plasma and validation of employed ELISA methods.

Authors:  D Larry Sparks; Richard J Kryscio; Marwan N Sabbagh; Chuck Ziolkowski; Yushun Lin; Lisa M Sparks; Carolyn Liebsack; Sherry Johnson-Traver
Journal:  Am J Neurodegener Dis       Date:  2012-05-15

8.  Bilirubin as a determinant for altered neurogenesis, neuritogenesis, and synaptogenesis.

Authors:  Adelaide Fernandes; Ana Sofia Falcão; Elsa Abranches; Evguenia Bekman; Domingos Henrique; Lorene M Lanier; Dora Brites
Journal:  Dev Neurobiol       Date:  2009-08       Impact factor: 3.964

9.  Mild therapeutic hypothermia alters neuron specific enolase as an outcome predictor after resuscitation: 97 prospective hypothermia patients compared to 133 historical non-hypothermia patients.

Authors:  Ingo G Steffen; Dietrich Hasper; Christoph J Ploner; Joerg C Schefold; Ekkehart Dietz; Frank Martens; Jens Nee; Anne Krueger; Achim Jörres; Christian Storm
Journal:  Crit Care       Date:  2010-04-19       Impact factor: 9.097

10.  Prognostic value of somatosensory evoked potentials, neuron-specific enolase, and S100 for short-term outcome in ischemic stroke.

Authors:  Walter F Haupt; Ghesal Chopan; Jan Sobesky; Wei-Chi Liu; Christian Dohmen
Journal:  J Neurophysiol       Date:  2015-12-23       Impact factor: 2.714

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.